Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Variant Bio is raising $6,699,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Andrew Farnum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Variant Bio

Variant Bio is developing therapies that will improve global health by studying the genes of people with exceptional health-related traits. There is a pressing need for new ways to treat disease, but drug development has become increasingly difficult due to high costs and failure rates. Human genetics has the power to transform drug development, because it uses human diversity to identify the basis of disease and resistance to it. Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.

To learn more about Variant Bio, visit http://www.variantbio.com/

Contact:
Andrew Farnum, Chief Executive Officer
206-719-6382
https://www.linkedin.com/in/andrew-farnum-4b180a1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved